The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 11 11 2022
revised: 28 06 2023
accepted: 07 08 2023
medline: 27 11 2023
pubmed: 1 9 2023
entrez: 31 8 2023
Statut: ppublish

Résumé

Biomarkers of tubular function such as epidermal growth factor (EGF) may improve prognostication of participants at highest risk for chronic kidney disease (CKD) after hospitalization. To examine this, we measured urinary EGF (uEGF) from samples collected in the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study, a multi-center, prospective, observational cohort of hospitalized participants with and without AKI. Cox proportional hazards regression was used to investigate the association of uEGF/Cr at hospitalization, three months post-discharge, and the change between these time points with major adverse kidney events (MAKE): CKD incidence, progression, or development of kidney failure. Clinical findings were paired with mechanistic studies comparing relative Egf expression in mouse models of kidney atrophy or repair after ischemia-reperfusion injury. MAKE was observed in 20% of 1,509 participants over 4.3 years of follow-up. Each 2-fold higher level of uEGF/Cr at three months was associated with decreased risk of MAKE (adjusted hazards ratio 0.46, 95% confidence interval: 0.39-0.55). Participants with the highest increase in uEGF/Cr from hospitalization to three-month follow-up had a lower risk of MAKE (adjusted hazards ratio 0.52; 95% confidence interval: 0.36-0.74) compared to those with the least change in uEGF/Cr. A model using uEGF/Cr at three months combined with clinical variables yielded moderate discrimination for MAKE (area under the curve 0.73; 95% confidence interval: 0.69-0.77) and strong discrimination for kidney failure at four years (area under the curve 0.96; 95% confidence interval: 0.92-1.00). Accelerated restoration of Egf expression in mice was seen in the model of adaptive repair after injury, compared to a model of progressive atrophy. Thus, urinary EGF/Cr may be a biomarker of distal tubular health, with higher concentrations and increased uEGF/Cr post-discharge independently associated with reduced risk of MAKE in hospitalized patients.

Identifiants

pubmed: 37652206
pii: S0085-2538(23)00601-4
doi: 10.1016/j.kint.2023.08.007
pii:
doi:

Substances chimiques

Epidermal Growth Factor 62229-50-9
Biomarkers 0

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1194-1205

Subventions

Organisme : NIDDK NIH HHS
ID : K01 DK120783
Pays : United States

Informations de copyright

Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Steven Menez (S)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Yumeng Wen (Y)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Leyuan Xu (L)

Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Dennis G Moledina (DG)

Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Heather Thiessen-Philbrook (H)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

David Hu (D)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Wassim Obeid (W)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Pavan K Bhatraju (PK)

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA; Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.

T Alp Ikizler (TA)

Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Edward D Siew (ED)

Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Vernon M Chinchilli (VM)

Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.

Amit X Garg (AX)

Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.

Alan S Go (AS)

Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

Kathleen D Liu (KD)

Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.

James S Kaufman (JS)

Division of Nephrology, New York University School of Medicine, New York, New York, USA; Divison of Nephrology, VA New York Harbor Healthcare System, New York, New York, USA.

Paul L Kimmel (PL)

National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA; National Institutes of Health, Bethesda, Maryland, USA.

Jonathan Himmelfarb (J)

Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Steven G Coca (SG)

Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Lloyd G Cantley (LG)

Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Chirag R Parikh (CR)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: chirag.parikh@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH